Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
21 hedge funds and large institutions have $2.11M invested in Sonnet BioTherapeutics in 2023 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 6 closing their positions.
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
31% more funds holding
Funds holding: 16 → 21 (+5)
0.08% less ownership
Funds ownership: 0.21% → 0.12% (-0.08%)
20% less capital invested
Capital invested by funds: $2.63M → $2.11M (-$525K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$832K |
| 2 |
Renaissance Technologies
New York
|
+$111K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$56.3K |
| 4 |
State Street
Boston,
Massachusetts
|
+$37.9K |
| 5 |
VF
Virtu Financial
New York
|
+$34.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$634K |
| 2 |
Walleye Capital
New York
|
-$599K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$343K |
| 4 |
AC
Ayrton Capital
Westport,
Connecticut
|
-$276K |
| 5 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$253K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Alyeska Investment Group
Chicago,
Illinois
| – | -$343K | -5,408 | Closed |
|
|
AC
27
Ayrton Capital
Westport,
Connecticut
| – | -$276K | -4,349 | Closed |
|
|
CH
28
CVI Holdings
Wilmington,
Delaware
| – | -$253K | -3,987 | Closed |
|
|
BFM
29
Boothbay Fund Management
New York
| – | -$49K | -774 | Closed |
|
SONN Hedge Fund Activity: Q2 2023 in Review
21 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q2 2023, worth a combined $2.11M — down 20% from $2.63M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new SONN positions and 6 closed out — a net gain of 5 holders — while 6 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, adding an estimated $832K. The largest seller was Anson Funds Management, exiting entirely with an estimated $634K sold.
- 21 institutional investors held Sonnet BioTherapeutics (SONN) as of Q2 2023, up from 16 in Q1 2023.
- Funds reported $2.11M of Sonnet BioTherapeutics stock for Q2 2023, down 20% quarter-over-quarter.
- 11 funds opened new Sonnet BioTherapeutics positions in Q2 2023 and 6 closed out, a net change of +5 holders.
- The largest Sonnet BioTherapeutics buyer in Q2 2023 was Sabby Management, an estimated $832K added.
- The largest Sonnet BioTherapeutics seller in Q2 2023 was Anson Funds Management, an estimated $634K sold.
Based on aggregated 13F filings for Q2 2023.